<DOC>
	<DOCNO>NCT01827046</DOCNO>
	<brief_summary>A phase III , randomize , case-controlled , open-label , 500-subject clinical trial minimally invasive surgery plus rt-PA treatment intracerebral hemorrhage ( ICH ) .</brief_summary>
	<brief_title>Minimally Invasive Surgery Plus Rt-PA ICH Evacuation Phase III</brief_title>
	<detailed_description>Primary Objectives : Efficacy : Demonstrate minimally invasive surgery ( MIS ) plus recombinant tissue plasminogen activator ( rt-PA ) three day improve functional outcome 12 % increase modify Rankin Scale ( mRS ) score 0-3 compare medically treated subject assess 180 day . Safety : Demonstrate early use MIS+rt-PA three day safe treatment ICH relative rate mortality , rebleeding , infection medically treat subject 30 day . Secondary Objective : Demonstrate end treatment volume percent ICH reduction MIS+rt-PA relate improved functional outcome , compare medically treated subject .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Spontaneous supratentorial ICH ≥ 30 mL diagnose use radiographic imaging ( computerized tomography ( CT ) , computerized tomography angiography ( CTA ) , etc . ) , Glasgow Coma Scale ( GCS ) ≤ 14 NIHSS ≥ 6 . Sixhour clot size equal previous clot size ( within 5 mL ) determine additional CT scan least 6 hour apart use ABC/2 method . Symptoms le 24 hour prior diagnostic CT ( dCT ) scan ( unknown time onset exclusionary ) . Ability randomize 12 72 hour dCT . Systolic Blood Pressure ( SBP ) &lt; 180 mmHg sustain six hour record close time randomization . Historical Rankin score 0 1 . Age ≥ 18 old . Infratentorial hemorrhage . Intraventricular hemorrhage ( IVH ) require treatment IVHrelated ( cast ) mass effect shift due trap ventricle . External ventricular drain ( EVD ) treat intracranial pressure ( ICP ) allow . Thalamic bleed apparent midbrain extension third nerve palsy dilate nonreactive pupil . Other ( supranuclear ) gaze abnormality exclusion . Note : Patients posterior fossa ICH cerebellar hematoma ineligible . Irreversible impaired brain stem function ( bilateral fix , dilate pupil extensor motor posturing ) , GCS ≤ 4 . Ruptured aneurysm , arteriovenous malformation ( AVM ) , vascular anomaly , Moyamoya disease , hemorrhagic conversion ischemic infarct , recurrence recent ( &lt; 1 year ) hemorrhage diagnose radiographic imaging . Patients unstable mass evolve intracranial compartment syndrome . Platelet count &lt; 100,000 , international normalize ratio ( INR ) &gt; 1.4 , elevate prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) . Any irreversible coagulopathy know clot disorder . Inability sustain INR ≤ 1.4 use short longactive procoagulants ( limited NovoSeven , Fresh Frozen Plasma ( FFP ) , and/or vitamin K ) . Subjects require longterm anticoagulation exclude . Reversal anticoagulation permit medically stable patient realistically tolerate short term risk reversal . Patient must require Coumadin ( anticoagulation ) first 30 day , normalized coagulation parameter must demonstrate , monitor closely maintained period brain instrumentation . Use Dabigatran , Apixaban , and/or Rivaroxaban ( similar medication similar medication class ) prior symptom onset . Internal bleeding , involve retroperitoneal site , gastrointestinal , genitourinary , respiratory tract . Superficial surface bleeding , observe mainly vascular puncture access site ( e.g. , venous cutdowns , arterial puncture , etc . ) site recent surgical intervention . Positive urine serum pregnancy test premenopausal female subject without documented history surgical sterilization . Allergy/sensitivity rtPA . Prior enrollment study . Participation concurrent interventional medical investigation clinical trial . Patients observational , natural history , and/or epidemiological study involve intervention eligible . Not expect survive day 365 visit due comorbidities and/or resuscitate ( DNR ) / intubate ( DNI ) status prior randomization . Any concurrent serious illness would interfere safety assessment include hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , immunologic , hematologic disease . Patients mechanical heart valve . Presence bioprosthetic valve ( ) permit . Known risk embolization , include history leave heart thrombus , mitral stenosis atrial fibrillation , acute pericarditis , subacute bacterial endocarditis . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . In investigator 's opinion , patient unstable would benefit specific intervention rather supportive care plus minus MIS+rtPA removal ICH . Inability unwillingness subject legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>intracerebral hemorrhage</keyword>
	<keyword>ICH</keyword>
	<keyword>brain hemorrhage</keyword>
	<keyword>minimally invasive surgery</keyword>
	<keyword>rt-PA</keyword>
</DOC>